Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03090464 · ClinicalTrials.gov registry record
A 6-month Clinical Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With T2DM
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 328
- Enrollment target
NCT03090464 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 328 participants.
The verdict
NCT03090464 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 328 participants
- Enrollment target
Study Summary
Type 2 diabetes mellitus is a complex, chronic disease that requires a comprehensive treatment plan aimed at meeting multitude therapeutic targets associated with micro- and macro-vascular risk reduction. There is evidence that patient support in various forms can have a significant positive impact on adherence to treatment and the meeting of targets in patients with type 2 diabetes mellitus. The purpose of this study is to evaluate if the use of a digital disease management tool (Smart phone- web portal-based tool), in addition to Standard of Care for T2DM, will improve glycemic control. Other variables important in T2DM (such as weight, blood pressure, and lipid levels), will also be evaluated along with patient-reported outcomes, such as satisfaction with treatment and adherence to their antihyperglycemic treatment. Study duration is 6 months
Interventions
- OTHER Use of digital disease management tool
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 328 participants |
| Start Date | 2017-05-08 |
| Est. Completion | 2018-05-21 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03090464
The ClinicalTrials.gov registry entry for NCT03090464 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 328 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Use of digital disease management tool is the first listed.
NCT03090464 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03090464 about?
NCT03090464 is a clinical study titled "A 6-month Clinical Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With T2DM". Type 2 diabetes mellitus is a complex, chronic disease that requires a comprehensive treatment plan aimed at meeting multitude therapeutic targets associated with micro- and macro-vascular risk reduction. There is evidence that patient support in various forms can have a significant positive impact ...
What is the current status of trial NCT03090464?
This trial is currently completed. The enrollment target is 328 participants. The study started on 2017-05-08. Estimated completion is 2018-05-21.
What interventions are being tested in trial NCT03090464?
The interventions under investigation include: Use of digital disease management tool (OTHER).
Who is sponsoring clinical trial NCT03090464?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.